| Year |
Citation |
Score |
| 2020 |
Levin-Epstein R, Cook RR, Wong JK, Stock RG, Jeffrey Demanes D, Collins SP, Aghdam N, Suy S, Mantz C, Katz AJ, Nickols NG, Miszczyk L, Napieralska A, Namysl-Kaletka A, Prionas ND, et al. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3,502 patients. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 32663537 DOI: 10.1016/J.Radonc.2020.07.014 |
0.337 |
|
| 2020 |
Parikh NR, Kishan AU, Kane N, Diaz-Perez S, Ganapathy E, Nazarian R, Felix C, Mathis C, Bradley M, Sachdeva A, Wyatt B, Basehart V, Zomorodian N, Lin L, King CR, ... ... Nickols NG, et al. Phase I Trial of Stereotactic Body Radiotherapy Neoadjuvant to Radical Prostatectomy for Patients with High-Risk Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 32562839 DOI: 10.1016/J.Ijrobp.2020.06.010 |
0.305 |
|
| 2020 |
Dang AT, Levin-Epstein RG, Shabsovich D, Cao M, King C, Chu FI, Mantz CA, Stephans KL, Reddy CA, Loblaw DA, Cheung P, Scorsetti M, Cozzi L, DeNittis AS, Wang Y, ... ... Nickols NG, et al. Gantry-Mounted Linear Accelerator-Based Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer. Advances in Radiation Oncology. 5: 404-411. PMID 32529134 DOI: 10.1016/J.Adro.2019.09.010 |
0.326 |
|
| 2020 |
Valle LF, Ruan D, Dang A, Levin-Epstein RG, Patel AP, Weidhaas JB, Nickols NG, Lee PP, Low DA, Qi XS, King CR, Steinberg ML, Kupelian PA, Cao M, Kishan AU. Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy. Frontiers in Oncology. 10: 786. PMID 32509582 DOI: 10.3389/Fonc.2020.00786 |
0.314 |
|
| 2020 |
Kishan AU, Romero T, Alshalalfa M, Liu Y, Tran PT, Nickols NG, Ye H, Sajed D, Rettig MB, Reiter RE, Garraway IP, Spratt DE, Freedland SJ, Zhao X, Li Z, et al. Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. European Urology. PMID 32461072 DOI: 10.1016/J.Eururo.2020.05.009 |
0.337 |
|
| 2020 |
Levin-Epstein R, Qiao-Guan G, Juarez JE, Shen Z, Steinberg ML, Ruan D, Valle L, Nickols NG, Kupelian PA, King CR, Cao M, Kishan AU. Clinical Assessment of Prostate Displacement and Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer. Frontiers in Oncology. 10: 539. PMID 32373529 DOI: 10.3389/Fonc.2020.00539 |
0.309 |
|
| 2020 |
Nickols NG, Ganapathy E, Nguyen C, Kane N, Lin L, Diaz-Perez S, Nazarian R, Kishan AU, King CR, Kupelian P, Rettig M, Steinberg ML, Cao M, Knudsen B, Chu F, et al. The intraprostatic immune balance after prostate SBRT in patients. Journal of Clinical Oncology. 38: 339-339. DOI: 10.1200/Jco.2020.38.6_Suppl.339 |
0.354 |
|
| 2020 |
Parikh NR, Chang EM, Nickols NG, Rettig M, Raldow AC, Steinberg ML, Koontz BF, Vapiwala N, Deville C, Feng FY, Spratt DE, Reiter RE, Phillips R, Tran PT, Kishan AU. Cost-effectiveness of upfront therapeutic options in low-volume de novo metastatic hormone-sensitive prostate cancer. Journal of Clinical Oncology. 38: 211-211. DOI: 10.1200/Jco.2020.38.6_Suppl.211 |
0.303 |
|
| 2020 |
Dadashian E, Nakazawa M, Parikh NR, Kalpage N, Nickols NG, Rettig M. Clinically relevant genomic alterations identified by targeted exome sequencing in U.S. veterans with prostate cancer. Journal of Clinical Oncology. 38: e17599-e17599. DOI: 10.1200/Jco.2020.38.15_Suppl.E17599 |
0.364 |
|
| 2020 |
Armstrong WR, Thin P, Nguyen K, Alano RM, Booker KM, Gartmann J, Lok V, Lira S, Czernin J, Kishan AU, Nickols NG, Calais J. Comparison of recurrence patterns after surgery and radiation therapy with 68Ga-PSMA-11 PET/CT in nonmetastatic castrate-sensitive prostate cancer patients: A single-center post-hoc retrospective analysis in 787 patients. Journal of Clinical Oncology. 38: 3577-3577. DOI: 10.1200/Jco.2020.38.15_Suppl.3577 |
0.322 |
|
| 2020 |
Valle L, Ruan D, Dang A, Levin-Epstein R, Patel A, Weidhaas J, Nickols N, Lee P, Low D, Qi S, King C, Steinberg M, Kupelian P, Cao M, Kishan A. Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy International Journal of Radiation Oncology Biology Physics. 108. DOI: 10.1016/J.Ijrobp.2020.02.626 |
0.331 |
|
| 2019 |
Kishan AU, Chu FI, King CR, Seiferheld W, Spratt DE, Tran P, Wang X, Pugh SE, Sandler KA, Bolla M, Maingon P, De Reijke T, Nickols NG, Rettig M, Drakaki A, et al. Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. European Urology. PMID 31718822 DOI: 10.1016/J.Eururo.2019.10.008 |
0.332 |
|
| 2019 |
Wang C, Raldow AC, Nickols NG, Nguyen PL, Spratt DE, Dess RT, Yu JB, King CR, Chu FI, Chamie K, Litwin MS, Saigal CS, Reiter RE, Liu ST, Rettig MB, et al. Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. European Urology Oncology. PMID 31411981 DOI: 10.1016/J.Euo.2019.01.006 |
0.32 |
|
| 2019 |
Jiang NY, Dang AT, Yuan Y, Chu FI, Shabsovich D, King CR, Collins SP, Aghdam N, Suy S, Mantz CA, Miszczyk L, Napieralska A, Namysl-Kaletka A, Bagshaw H, Prionas N, ... ... Nickols NG, et al. Multi-institutional Analysis of Prostate-Specific Antigen Kinetics Following Stereotactic Body Radiotherapy (SBRT). International Journal of Radiation Oncology, Biology, Physics. PMID 31276777 DOI: 10.1016/J.Ijrobp.2019.06.2539 |
0.337 |
|
| 2019 |
Yuan Y, Aghdam N, King C, Fuller D, Weng J, Chu FI, Mardirossian G, Patel A, Nickols NG, Kupelian PA, Steinberg ML, Collins SP, Kishan AU. Testosterone Levels and Sexual Quality of Life Following Stereotactic Body Radiotherapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials. International Journal of Radiation Oncology, Biology, Physics. PMID 31108142 DOI: 10.1016/J.Ijrobp.2019.05.014 |
0.301 |
|
| 2019 |
Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, ... ... Nickols NG, et al. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. European Urology. PMID 30992160 DOI: 10.1016/J.Eururo.2019.03.022 |
0.334 |
|
| 2019 |
Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, ... ... Nickols NG, et al. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. Bmc Cancer. 19: 291. PMID 30935383 DOI: 10.1186/S12885-019-5496-5 |
0.316 |
|
| 2019 |
Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, et al. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 30804427 DOI: 10.1038/S41391-019-0134-5 |
0.332 |
|
| 2019 |
Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. Randomized phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.7_Suppl.Tps136 |
0.327 |
|
| 2019 |
Jiang NY, King CR, Katz AJ, Collins SP, Aghdam N, Suy S, Stephans KL, Reddy CA, Kaplan ID, Appelbaum L, Dang A, Yuan Y, Nickols NG, Steinberg ML, Kupelian P, et al. Multi-institutional analysis of high-risk prostate cancer patients treated with stereotactic body radiotherapy. Journal of Clinical Oncology. 37: 51-51. DOI: 10.1200/Jco.2019.37.7_Suppl.51 |
0.333 |
|
| 2019 |
Kishan AU, Romero T, Elashoff D, Grogan T, Rettig M, Reiter RE, Tran PT, Nguyen PL, Nickols NG, Davicioni E, Spratt DE, Feng FY, Weidhaas JB. Genomic biomarkers to predict outcome in Gleason Score 9-10 disease. Journal of Clinical Oncology. 37: 44-44. DOI: 10.1200/Jco.2019.37.7_Suppl.44 |
0.306 |
|
| 2019 |
Parikh NR, Nickols NG, Rettig M, King CR, Raldow AC, Steinberg ML, Tran PT, Kishan AU. Cost-effectiveness of metastasis-directed therapy in the setting of oligometastatic hormone-sensitive prostate cancer. Journal of Clinical Oncology. 37: 147-147. DOI: 10.1200/Jco.2019.37.7_Suppl.147 |
0.336 |
|
| 2019 |
Cao M, Qiao-Guan G, Zhouhuizi S, Steinberg ML, Nickols NG, Kupelian PA, King CR, Kishan AU. Clinical Assessment of the Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.788 |
0.322 |
|
| 2019 |
Nickols N, Kishan A, Kane N, Diaz-Perez S, Ganapathy E, Nazarian R, Felix C, Mathis C, Kwak J, Basehart V, Zomorodian N, King C, Kupelian P, Rettig M, Steinberg M, et al. Phase I Trial of Stereotactic Body Radiotherapy Neoadjuvant to Radical Prostatectomy for Patients with Unfavorable and High-Risk Non-Metastatic Prostate Cancer: Feasibility And Safety International Journal of Radiation Oncology*Biology*Physics. 105: E298. DOI: 10.1016/J.Ijrobp.2019.06.1849 |
0.311 |
|
| 2019 |
Kishan A, Romero T, Grogan T, Alshalalfa M, Boutros P, Rettig M, Reiter R, Tran P, Nguyen P, Nickols N, Davicioni E, Spratt D, Feng F, Den R, Freedland S, et al. Transcriptomic Heterogeneity in Pathological Grade Group 5 Prostate Cancer: Implications for Biomarker Discovery International Journal of Radiation Oncology*Biology*Physics. 105: E286-E287. DOI: 10.1016/J.Ijrobp.2019.06.1823 |
0.317 |
|
| 2019 |
Jiang N, Wong J, Horwitz E, Stock R, Collins S, Suy S, Mantz C, Katz A, Miszczyk L, Bagshaw H, Prionas N, Buyyounouski M, Zaorsky N, Nickols N, King C, et al. Prostate-Specific Antigen Kinetics Following Various Radiotherapy Modalities: A Multi-Institutional Analysis International Journal of Radiation Oncology*Biology*Physics. 105: E283. DOI: 10.1016/J.Ijrobp.2019.06.1816 |
0.315 |
|
| 2018 |
Yuan Y, Kishan AU, Nickols NG. Treatment of the primary tumor in metastatic prostate cancer. World Journal of Urology. PMID 30456709 DOI: 10.1007/S00345-018-2552-8 |
0.353 |
|
| 2018 |
Kishan AU, Wang X, Seiferheld W, Collette L, Sandler KA, Sandler HM, Bolla M, Maingon P, De Reijke T, Hanks GE, Nickols NG, Rettig M, Drakaki A, Reiter RE, Spratt DE, et al. Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis. Jama Oncology. PMID 30326032 DOI: 10.1001/Jamaoncol.2018.3732 |
0.305 |
|
| 2018 |
Diaz-Perez S, Kane N, Kurmis AA, Yang F, Kummer NT, Dervan PB, Nickols NG. Interference with DNA repair after ionizing radiation by a pyrrole-imidazole polyamide. Plos One. 13: e0196803. PMID 29715291 DOI: 10.1371/Journal.Pone.0196803 |
0.626 |
|
| 2018 |
Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Matthew RB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG. Potential impact of Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29653978 DOI: 10.2967/Jnumed.118.209387 |
0.304 |
|
| 2018 |
Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, ... ... Nickols NG, et al. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. Jama. 319: 896-905. PMID 29509865 DOI: 10.1001/Jama.2018.0587 |
0.307 |
|
| 2018 |
Calais J, Cao M, Nickols NG. The Utility of PET/CT in External Radiation Therapy Planning of Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29301928 DOI: 10.2967/Jnumed.117.196444 |
0.319 |
|
| 2018 |
Kishan A, Katz A, Mantz C, Chu F, Appelbaum L, Loblaw D, Kaplan I, Pham H, Buyyounouski M, Fuller D, Meier R, Collins S, Shaverdian N, Dang A, Yuan Y, ... ... Nickols N, et al. Long-Term Outcomes of Stereotactic Body Radiation Therapy for Low and Intermediate-Risk Prostate Adenocarcinoma: A Multi-Institutional Consortium Study International Journal of Radiation Oncology*Biology*Physics. 102: S106. DOI: 10.1200/Jco.2018.36.6_Suppl.84 |
0.313 |
|
| 2018 |
Fendler W, Calais J, Gartmann J, Nickols NG, Reiter RE, Rettig M, Hope TA, Slavik R, Gupta P, Quon A, Allen-Auerbach M, Herrmann K, Czernin J, Eiber M. Accuracy of 68Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial. Journal of Clinical Oncology. 36: 5001-5001. DOI: 10.1200/Jco.2018.36.15_Suppl.5001 |
0.304 |
|
| 2018 |
Diaz-Perez S, Kane N, Yang F, Kurmis A, Kummer N, Dervan P, Nickols N. Radiosensitization by a Pyrrole-Imidazole Polyamide Through Interference with DNA Repair International Journal of Radiation Oncology*Biology*Physics. 102: e155. DOI: 10.1016/J.Ijrobp.2018.07.604 |
0.659 |
|
| 2018 |
Wang C, Raldow A, King CR, Kupelian PA, Nickols N, Chang AJ, Steinberg ML, Spratt DE, Nguyen PL, Kishan AU. Racial Disparity in Androgen Deprivation Therapy Utilization for Men with High-Risk Prostate Cancer Treated with Intensity-Modulated Radiation Therapy in the Modern Era – A SEER-Medicare Linked Database Analysis International Journal of Radiation Oncology Biology Physics. 102. DOI: 10.1016/J.Ijrobp.2018.07.286 |
0.321 |
|
| 2018 |
Wang C, Kishan AU, King CR, Kupelian PA, Nickols N, Chang AJ, Steinberg ML, Chu FI, Raldow A. Racial Disparity in Treatment Outcomes for Men with High-Risk Prostate Cancer in the Modern Era – A SEER-Medicare Linked Database Analysis International Journal of Radiation Oncology Biology Physics. 102. DOI: 10.1016/J.Ijrobp.2018.07.1208 |
0.312 |
|
| 2018 |
Nickols N, Lin L, Kane N, Kobayashi N, Reiter R. High Dose per Fraction Radiation Therapy Increases Both Tumor-Infiltrating Lymphocytes and Suppressive Immune Cells in Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 102: S203-S204. DOI: 10.1016/J.Ijrobp.2018.07.107 |
0.353 |
|
| 2018 |
Dang AT, King CR, Shabsovich D, Mantz CA, Stephans KL, Loblaw DA, Cheung P, Scorsetti M, Cozzi L, DeNittis AS, Wang Y, Nickols N, Kupelian PA, Steinberg ML, Kishan AU. Outcomes of Stereotactic Body Radiation Therapy Delivered by Gantry-Based Linear Accelerators for Low and Intermediate-Risk Prostate Adenocarcinoma: A Multi-institutional Study International Journal of Radiation Oncology Biology Physics. 102. DOI: 10.1016/J.Ijrobp.2018.06.272 |
0.3 |
|
| 2017 |
Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler KA, Chu FI, King CR, Steinberg ML, Rausher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, ... ... Nickols NG, et al. (68)Ga-PSMA PET/CT mapping of prostate cancer biochemical recurrence following radical prostatectomy in 270 patients with PSA<1.0ng/ml: Impact on Salvage Radiotherapy Planning. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29123013 DOI: 10.2967/Jnumed.117.201749 |
0.326 |
|
| 2017 |
Hegde JV, Demanes DJ, Veruttipong D, Raince J, Park SJ, Raman SS, Nickols NG, King CR, Kishan AU, Steinberg ML, Kamrava M. Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy. Brachytherapy. PMID 28807747 DOI: 10.1016/J.Brachy.2017.07.008 |
0.32 |
|
| 2017 |
Kurmis AA, Yang F, Welch TR, Nickols NG, Dervan PB. A pyrrole-imidazole polyamide is active against enzalutamide-resistant prostate cancer. Cancer Research. PMID 28360139 DOI: 10.1158/0008-5472.Can-16-2503 |
0.643 |
|
| 2017 |
Kishan AU, Ciezki JP, Shaikh T, Stock R, Merrick GS, Demanes DJ, Wang J, Said JW, Fiano R, Raghavan G, Sandler KA, Reddy CA, Nickols NG, Aronson WJ, Sadeghi A, et al. Radiotherapy versus radical prostatectomy for Gleason score 9-10 prostate adenocarcinoma: A multi-institutional comparative analysis of 1001 patients treated in the modern era. Journal of Clinical Oncology. 35: 7-7. DOI: 10.1200/Jco.2017.35.6_Suppl.7 |
0.323 |
|
| 2017 |
Kishan A, Wang X, Sandler K, Nickols N, Steinberg M, King C. Longer-Term Androgen Deprivation Therapy Improves Cancer-Specific Survival in Patients With Gleason Score 9-10 Prostate Adenocarcinoma: An Individual Patient-Level Meta-analysis of RTOG 8531, 8610, and 9202 International Journal of Radiation Oncology*Biology*Physics. 99: S133-S134. DOI: 10.1016/J.Ijrobp.2017.06.311 |
0.333 |
|
| 2017 |
Kishan AU, Ciezki JP, Ross AE, Cook RR, Shaikh T, Stock RG, Merrick GS, Demanes DJ, Alam R, Spratt DE, Abu-Isa EI, Wedde T, Lilleby W, Sandler KA, Song D, ... ... Nickols N, et al. Extremely Dose Escalated Radiation Therapy Improves Cancer-Specific Survival Compared With Radical Prostatectomy or Conventionally Dose-Escalated Radiation Therapy in Gleason Score 9-10 Prostate Adenocarcinoma: A Multi-institutional Analysis of 1403 Patie International Journal of Radiation Oncology Biology Physics. 99. DOI: 10.1016/J.Ijrobp.2017.06.306 |
0.317 |
|
| 2017 |
Sandler KA, Cook RR, Ciezki JP, Shaikh T, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde T, Lilleby W, Krauss DJ, Song D, Alam R, Reddy CA, ... Nickols N, et al. Whole Pelvis Radiation Therapy Does Not Significantly Improve Prostate-Cancer Specific Survival in Patients With Gleason Score 9-10 Prostate Adenocarcinoma: An Analysis of 942 Patients Treated in the Modern Era International Journal of Radiation Oncology Biology Physics. 99. DOI: 10.1016/J.Ijrobp.2017.06.1231 |
0.323 |
|
| 2016 |
Kishan AU, Shaikh T, Wang PC, Reiter RE, Said J, Raghavan G, Nickols NG, Aronson WJ, Sadeghi A, Kamrava M, Demanes DJ, Steinberg ML, Horwitz EM, Kupelian PA, King CR. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. European Urology. PMID 27452951 DOI: 10.1016/J.Eururo.2016.06.046 |
0.329 |
|
| 2015 |
Kishan AU, Wang PC, Upadhyaya SK, Hauswald H, Demanes DJ, Nickols NG, Kamrava M, Sadeghi A, Kupelian PA, Steinberg ML, Prionas ND, Buyyounouski MK, King CR. SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer. Practical Radiation Oncology. PMID 26850649 DOI: 10.1016/J.Prro.2015.11.002 |
0.34 |
|
| 2015 |
Kummer N, Yang F, Dervan P, Nickols N. Radiosensitization by DNA, Binding Pyrrole, Imidazole Polyamides International Journal of Radiation Oncology*Biology*Physics. 93: E537-E538. DOI: 10.1016/J.Ijrobp.2015.07.1923 |
0.689 |
|
| 2015 |
Kishan AU, Demanes DJ, Wang J, Hauswald H, Nickols N, Kamrava M, Kupelian PA, Steinberg ML, King CR. SBRT and HDR Brachytherapy Produce Lower PSA Nadirs and More Rapid PSA Decline Than Conventionally Fractionated IMRT in Patients With Low- or Intermediate-Risk Prostate Cancer International Journal of Radiation Oncology Biology Physics. 93. DOI: 10.1016/J.Ijrobp.2015.07.1092 |
0.324 |
|
| 2014 |
Sollier E, Go DE, Che J, Gossett DR, O'Byrne S, Weaver WM, Kummer N, Rettig M, Goldman J, Nickols N, McCloskey S, Kulkarni RP, Di Carlo D. Size-selective collection of circulating tumor cells using Vortex technology Lab On a Chip - Miniaturisation For Chemistry and Biology. 14: 63-77. PMID 24061411 DOI: 10.1039/C3Lc50689D |
0.314 |
|
| 2014 |
Mysore VS, Nickols NG, Szablowski J, Dervan P, Lichtenstein A, Frost PJ. Abstract 5132: Targeting hypoxia-mediated gene transcription with a novel polyamide drug designed to disrupt the HIF1α/β heterodimer binding overcomes resistance to hypoxia in myeloma cell lines Cancer Research. 74: 5132-5132. DOI: 10.1158/1538-7445.Am2014-5132 |
0.766 |
|
| 2013 |
Yang F, Nickols NG, Li BC, Szablowski JO, Hamilton SR, Meier JL, Wang CM, Dervan PB. Animal toxicity of hairpin pyrrole-imidazole polyamides varies with the turn unit. Journal of Medicinal Chemistry. 56: 7449-57. PMID 24015881 DOI: 10.1021/Jm401100S |
0.761 |
|
| 2013 |
Nickols NG, Szablowski JO, Hargrove AE, Li BC, Raskatov JA, Dervan PB. Activity of a Py-Im polyamide targeted to the estrogen response element. Molecular Cancer Therapeutics. 12: 675-84. PMID 23443804 DOI: 10.1158/1535-7163.Mct-12-1040 |
0.761 |
|
| 2013 |
Yang F, Nickols NG, Li BC, Marinov GK, Said JW, Dervan PB. Antitumor activity of a pyrrole-imidazole polyamide. Proceedings of the National Academy of Sciences of the United States of America. 110: 1863-8. PMID 23319609 DOI: 10.1073/Pnas.1222035110 |
0.755 |
|
| 2013 |
Nickols NG, Yang F, Li BC, Szablowski JO, Wang C, Dervan PB. A second-generation DNA-binding pyrrole-imidazole polyamide with antitumor activity. Journal of Clinical Oncology. 31: e13588-e13588. DOI: 10.1200/Jco.2013.31.15_Suppl.E13588 |
0.795 |
|
| 2013 |
Nickols NG, Yang F, Li BC, Marinov GK, Said JW, Dervan PB. Abstract 1130: Antitumor activity of a pyrrole-imidazole polyamide in three tumor xenograft models. Cancer Research. 73: 1130-1130. DOI: 10.1158/1538-7445.Am2013-1130 |
0.7 |
|
| 2013 |
Sollier E, Che J, Go DE, Weaver WM, Kummer N, Rettig M, Goldman J, Nickols N, Carlo DD, Kulkarni RP. Abstract A197: Size-selective isolation of viable and pure CTCs for molecular analysis using vortex technology. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A197 |
0.335 |
|
| 2013 |
Nickols N, Yang F, Ratikan J, Li B, McBride W, Dervan P. Radiosensitization by High Affinity Programmable Minor Groove Binders International Journal of Radiation Oncology*Biology*Physics. 87: S651-S652. DOI: 10.1016/J.Ijrobp.2013.06.1725 |
0.742 |
|
| 2012 |
Raskatov JA, Nickols NG, Hargrove AE, Marinov GK, Wold B, Dervan PB. Gene expression changes in a tumor xenograft by a pyrrole-imidazole polyamide. Proceedings of the National Academy of Sciences of the United States of America. 109: 16041-5. PMID 22988074 DOI: 10.1073/Pnas.1214267109 |
0.799 |
|
| 2012 |
Synold TW, Xi B, Wu J, Yen Y, Li BC, Yang F, Phillips JW, Nickols NG, Dervan PB. Single-dose pharmacokinetic and toxicity analysis of pyrrole-imidazole polyamides in mice. Cancer Chemotherapy and Pharmacology. 70: 617-25. PMID 22907527 DOI: 10.1007/S00280-012-1954-3 |
0.688 |
|
| 2009 |
Muzikar KA, Nickols NG, Dervan PB. Repression of DNA-binding dependent glucocorticoid receptor-mediated gene expression. Proceedings of the National Academy of Sciences of the United States of America. 106: 16598-603. PMID 19805343 DOI: 10.1073/Pnas.0909192106 |
0.789 |
|
| 2007 |
Nickols NG, Jacobs CS, Farkas ME, Dervan PB. Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface. Acs Chemical Biology. 2: 561-71. PMID 17708671 DOI: 10.1021/Cb700110Z |
0.788 |
|
| 2007 |
Nickols NG, Dervan PB. Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proceedings of the National Academy of Sciences of the United States of America. 104: 10418-23. PMID 17566103 DOI: 10.1073/Pnas.0704217104 |
0.64 |
|
| 2007 |
Nickols NG, Jacobs CS, Farkas ME, Dervan PB. Improved nuclear localization of DNA-binding polyamides. Nucleic Acids Research. 35: 363-70. PMID 17175539 DOI: 10.1093/Nar/Gkl1042 |
0.796 |
|
| 2004 |
Olenyuk BZ, Zhang GJ, Klco JM, Nickols NG, Kaelin WG, Dervan PB. Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proceedings of the National Academy of Sciences of the United States of America. 101: 16768-73. PMID 15556999 DOI: 10.1073/Pnas.0407617101 |
0.578 |
|
| 2004 |
Edelson BS, Best TP, Olenyuk B, Nickols NG, Doss RM, Foister S, Heckel A, Dervan PB. Influence of structural variation on nuclear localization of DNA-binding polyamide-fluorophore conjugates. Nucleic Acids Research. 32: 2802-18. PMID 15155849 DOI: 10.1093/Nar/Gkh609 |
0.685 |
|
| 2003 |
Best TP, Edelson BS, Nickols NG, Dervan PB. Nuclear localization of pyrrole-imidazole polyamide-fluorescein conjugates in cell culture. Proceedings of the National Academy of Sciences of the United States of America. 100: 12063-8. PMID 14519850 DOI: 10.1073/Pnas.2035074100 |
0.751 |
|
| Show low-probability matches. |